You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T790M negative

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Bronchial Tumors Trial in Germany, Spain (EGF816, Trametinib)

Recruiting
  • Bronchial Neoplasms
  • Cologne, Germany
  • +6 more
Nov 2, 2022

NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Kashiwa, Chiba, Japan
  • +3 more
Jan 31, 2023

NSCLC Trial in China (Drug intervention)

Active, not recruiting
  • NSCLC
  • Drug intervention
  • Nanjing, Jiangsu, China
  • +4 more
Sep 28, 2020

Small Cell Carcinoma, NSCLC, Neuroendocrine Tumors Trial in United States (RRx-001, Cisplatin, Etoposide)

Active, not recruiting
  • Small Cell Carcinoma
  • +3 more
  • Palo Alto, California
  • +9 more
May 12, 2022

Lung Cancer Stage IV, EGFR T790M Trial in Seoul (Lazertinib)

Not yet recruiting
  • Lung Cancer Stage IV
  • EGFR T790M
  • Seoul, MA, Korea, Republic of
    Samsung Medical Center
Jan 26, 2023

EGFR T790M, Osimertinib, NSCLC Trial in Beijing (Osimertinib)

Recruiting
  • EGFR T790M
  • +3 more
  • Beijing, Beijing, China
    Junling Li
Jul 21, 2022

Combination of Anlotinib and JS001 in EGFR-TKI Resistant

Unknown status
  • NSCLC Stage IV
  • +3 more
    • Shanghai, China
      Shanghai Changzheng Hospital
    Oct 3, 2019

    Osimertinib for Russian EGFR T790M Mutation-positive NSCLC

    Recruiting
    • Non Small Cell Lung Cancer
    • +2 more
      • Moscow, Russian Federation
        Federal State Budgetary Institution National Medical Research Ce
      Mar 29, 2022

      Metastatic Lung Non-Small Cell Carcinoma, EGFR T790M Trial in Seoul (Lazertinib)

      Not yet recruiting
      • Metastatic Lung Non-Small Cell Carcinoma
      • EGFR T790M
      • Seoul, Korea, Republic of
        Samsung Medical Center
      May 18, 2022

      Either EML4-ALK Gene Rearrangements or T790M EGFR Mutation in

      Active, not recruiting
      • Carcinoma, Non-Small-Cell Lung
        • Hollywood, Florida
        • +1 more
        Sep 29, 2021

        Lung Cancer Trial in Boston, Nashville

        Active, not recruiting
        • Lung Cancer
          • Boston, Massachusetts
          • +1 more
          Dec 28, 2022

          Non Small Cell Lung Cancer Metastatic Trial in Worldwide (Osimertinib, Bevacizumab)

          Active, not recruiting
          • Non Small Cell Lung Cancer Metastatic
          • Dublin, Ireland
          • +24 more
          Aug 23, 2022

          Lung Cancer Trial (Lazertinib 240 mg)

          Approved for marketing
          • Lung Cancer
          • Lazertinib 240 mg
          • (no location specified)
          Feb 15, 2022

          NSCLC With EGFR T790M Mutation, With Brain and/or Leptomeningeal Metastasis, Failed Tyrosine Kinase Inhibitors Trial in Seoul

          Active, not recruiting
          • Non-Small Cell Lung Cancer With EGFR T790M Mutation
          • +2 more
          • Seoul, Korea, Republic of
            Department of Medicine, Samsung Medical Center, Sungkyunkwan Uni
          Aug 8, 2021

          Osimertinib for HK Chinese With Metastatic T790M Mutated

          Completed
          • Non-small Cell Lung Cancer
          • Hong Kong, China
          • +3 more
          Sep 7, 2021

          Non Small Cell Lung Cancer Trial in Worldwide (AZD9291)

          Active, not recruiting
          Has Results
          • Non Small Cell Lung Cancer
          • La Jolla, California
          • +43 more
          Nov 25, 2022

          Negative T790M Mutation and Met Amplification Trial in Beijing (Glumetinib)

          Unknown status
          • Negative T790M Mutation and Met Amplification
          • Beijing, Beijing, China
            Beijing Cancer Hospital
          Apr 7, 2020

          Lung Cancer Trial in Worldwide (Erlotinib, Bevacizumab)

          Completed
          Has Results
          • Lung Cancer
          • Caen, France
          • +47 more
          Aug 23, 2022

          NSCLC Trial in Beijing, Nanjing, Suzhou (BPI-7711 Capsule)

          Completed
          • Non-small Cell Lung Cancer
          • BPI-7711 Capsule
          • Beijing, Beijing, China
          • +3 more
          May 13, 2022

          Osimertinib in Advanced Non-Small Cell Lung Cancer EGFR-T790M

          Completed
          • Non Small Cell Lung Cancer
          • Oviedo, Asturias, Spain
          • +30 more
          Jun 1, 2022

          NSCLC Trial in Worldwide (PF-06747775, Palbociclib, Avelumab)

          Terminated
          Has Results
          • Non-Small Cell Lung Cancer
          • La Jolla, California
          • +14 more
          May 13, 2021

          NSCLC Trial (Chemotherapy, Alflutinib plus chemo)

          Not yet recruiting
          • NSCLC
          • (no location specified)
          Jan 25, 2022

          Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer Trial run by the NCI (Brachyury-TRICOM, Entinostat, M7824)

          Terminated
          Has Results
          • Breast Cancer
          • +4 more
          • Brachyury-TRICOM
          • +3 more
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          Dec 9, 2021

          Carcinoma, Ductal, Breast, Breast Cancer, Breast Tumor Trial in Worldwide (G1T38, Fulvestrant)

          Active, not recruiting
          • Carcinoma, Ductal, Breast
          • +2 more
          • Sofia, Bulgaria
          • +7 more
          Aug 1, 2022

          Lung Tumors, EGFR Gene Mutations Trial in Hwasun (Osimertinib)

          Completed
          • Lung Neoplasms
          • EGFR Gene Mutations
          • Hwasun, Jeonnam, Korea, Republic of
            Chonnam National University Hwasun Hospital
          Aug 1, 2021